More Hoosiers Facing Alzheimer’s Diagnoses As Caregiver Costs Rise
A new study showed costs are rising for caring for Hoosiers with Alzheimer’s disease and forms of dementia.
Read MoreA new study showed costs are rising for caring for Hoosiers with Alzheimer’s disease and forms of dementia.
Read MoreThe European Medicines Agency, citing the potentially dangerous risk of brain swelling and hemorrhage, rejected Eli Lilly and Co.’s new Alzheimer’s disease drug Kisunla.
Read MoreNew research directed at earlier detection of Alzheimer’s disease has produced a more promising method for diagnosis.
Read MoreIndiana doctors have created an Alzheimer’s disease and related dementia care model that helps unpaid family caregivers as much as it helps the patient.Â
Read MoreINDIANAPOLIS — The Alzheimer’s Association offers open support groups to provide caregivers with the opportunity to share their experiences and receive support from others living with Alzheimer’s disease. Feeling connected on the journey of Alzheimer’s disease can be an integral part of coping with the diagnosis and becoming … Read More
Eli Lilly and Company (NYSE: LLY) and AstraZeneca yesterday announced enrollment of the first patient into AMARANTH, a Phase II/III study of an oral beta secretase cleaving enzyme (BACE) inhibitor currently in development as a potential treatment for Alzheimer’s disease. AZD3293, also known as LY3314814, has been shown … Read More
Eli Lilly and Company today provided an update on the next steps planned for solanezumab, its Phase 3 monoclonal antibody being studied as a potential therapy for patients with mild Alzheimer’s disease. Following discussions with regulators in the U.S., Europe and Canada, Lilly plans to conduct an additional … Read More
Eli Lilly and Company (NYSE: LLY) today announced that the primary endpoints, both cognitive and functional, were not met in either of the two Phase 3, double-blind, placebo-controlled solanezumab EXPEDITION trials in patients with mild-to-moderate Alzheimer’s disease. However, a pre-specified secondary analysis of pooled data across both trials … Read More